HLNCF (Haleon) Equity-to-Asset : 0.47 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Haleon's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $20,437 Mil. Haleon's Total Assets for the quarter that ended in Dec. 2024 was $43,382 Mil. Therefore, Haleon's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.47.

The historical rank and industry rank for Haleon's Equity-to-Asset or its related term are showing as below:

HLNCF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47 Med: 0.63 Max: 0.77
Current: 0.47

During the past 6 years, the highest Equity to Asset Ratio of Haleon was 0.77. The lowest was 0.47. And the median was 0.63.

HLNCF's Equity-to-Asset is ranked worse than
67.47% of 1033 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs HLNCF: 0.47

Haleon Equity-to-Asset Historical Data

The historical data trend for Haleon's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Equity-to-Asset Chart

Haleon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Equity-to-Asset

Get a 7-Day Free Trial

0.77

0.47

0.49

0.47

Haleon Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial												0.49	-	0.50	-	0.47

Competitive Comparison of Haleon's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Haleon's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

Haleon Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Haleon's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	20437.421	/	43381.795
	=	0.47

Haleon's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	20437.421	/	43381.795
	=	0.47

Haleon (OTCPK:HLNCF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Haleon Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Haleon's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (OTCPK:HLNCF) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

HLN:USA HLN1:Mexico HLN:Mexico HLNl:UK HLN:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.